Cargando…
NSAIDs Modulate Clonal Evolution in Barrett's Esophagus
Cancer is considered an outcome of decades-long clonal evolution fueled by acquisition of somatic genomic abnormalities (SGAs). Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce cancer risk, including risk of progression from Barrett's esophagus (BE) to esophageal adenoca...
Autores principales: | Kostadinov, Rumen L., Kuhner, Mary K., Li, Xiaohong, Sanchez, Carissa A., Galipeau, Patricia C., Paulson, Thomas G., Sather, Cassandra L., Srivastava, Amitabh, Odze, Robert D., Blount, Patricia L., Vaughan, Thomas L., Reid, Brian J., Maley, Carlo C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681672/ https://www.ncbi.nlm.nih.gov/pubmed/23785299 http://dx.doi.org/10.1371/journal.pgen.1003553 |
Ejemplares similares
-
NSAID use and somatic exomic mutations in Barrett’s esophagus
por: Galipeau, Patricia C., et al.
Publicado: (2018) -
Correction to: NSAID use and somatic exomic mutations in Barrett’s esophagus
por: Galipeau, Patricia C., et al.
Publicado: (2019) -
p16 Mutation Spectrum in the Premalignant Condition Barrett's Esophagus
por: Paulson, Thomas G., et al.
Publicado: (2008) -
Within‐patient phylogenetic reconstruction reveals early events in Barrett’s Esophagus
por: Smith, Lucian P., et al.
Publicado: (2020) -
NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma
por: Galipeau, Patricia C, et al.
Publicado: (2007)